Skip to main content
  • MEETINGS
  • JOBS/RFPs
  • FUNDING
 

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Home

Scaleup of Versatile, Fully Automated, Microfluidic Cell Culture System (RT1-01024-1)

Marc Unger
Fluidigm
Status: Active

Public Abstract (provided by applicant)

We are proposing to optimize and scale up a highly advanced (microfluidic) cell culture system into manufacturable form. This system will allow researchers to:

  1. Identify stem cell culture and differentiation conditions
  2. Identify genes and small molecules effecting stem cell self-renewal and differentiation, and
  3. Identify genes and small molecules involving or effecting reprogramming of differentiated cells.

...much more rapidly and efficiently than they have been able to in the past.

Reprogramming a patient's own differentiated cells (e.g. skin cells) into stem cells overcomes the ethical and immunological barriers to theraputic usage which are present with the use of embryonic stem cells. These stem cells can be used in cell based therapy, tissue or organ repair, and potentially even organ reconstruction. Understanding what controls stem cells to differentiate into a desired type of cell helps directly in the development of theraputic applications. Thus, this tool will help both to determine conditions to convert differentiated cells into stem cells, and to develop therapies using the resulting stem cells.

Statement of Benefit to California (provided by applicant)

The system proposed here will allow us to

  1. Identify stem cell culture and differentiation conditions
  2. Identify genes and small molecules effecting stem cell self-renewal and differentiation, and
  3. Identify genes and small molecules involving or effecting reprogramming differentiated cells.

These capabilities will accelerate stem cell research in California. Since the grant will support work done in South San Francisco and San Diego, and the end result may be the creation of a commercial product, there is a direct economic multiplier effect for the resources invested.

More importantly, the identification of conditions which enable the reprogramming of differentiated cells will enable new therapies. Patient specific pluripotent stem cells can be used in cell based therapy, tissue or organ repair, and even organ reconstruction. The availability of powerful tools in California will help ensure that these new therapies are pioneered in California, leading both to job creation and the availability of the most advanced medical care in the world for California citizens.

Newsletter Sign-Up

Receive press releases, funding announcements or other news from CIRM.

>> Click here to sign up

Follow Us

Facebook Updates
YouTube Videos
Twitter
Flickr Images
LinkedIn
Research Blog
RSS Feeds

 

Bookmark and Share
  • Contact Us
  • Privacy Policy
  • Accessibility
  • Site Map
© 2009 California Institute For Regenerative Medicine